Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine.
COVID-19
Omicron
mRNA vaccine
older adults
postvaccination infection
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
03
10
2022
accepted:
08
02
2023
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
Longer-term immune response data after 3 doses of coronavirus disease 2019 (COVID-19) mRNA vaccine remain limited, particularly among older adults and after Omicron breakthrough infection. We quantified wild-type- and Omicron-specific serum immunoglobulin (Ig)G levels, angiotensin-converting enzyme 2 displacement activities, and live virus neutralization up to 6 months after third dose in 116 adults aged 24-98 years who remained COVID-19 naive or experienced their first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during this time. Among the 78 participants who remained COVID-19 naive throughout follow up, wild-type- and Omicron-BA.1-specific IgG concentrations were comparable between younger and older adults, although BA.1-specific responses were consistently significantly lower than wild-type-specific responses in both groups. Wild-type- and BA.1-specific IgG concentrations declined at similar rates in COVID-19-naive younger and older adults, with median half-lives ranging from 69 to 78 days. Antiviral antibody functions declined substantially over time in COVID-19-naive individuals, particularly in older adults: by 6 months, BA.1-specific neutralization was undetectable in 96% of older adults, versus 56% of younger adults. Severe acute respiratory syndrome coronavirus 2 infection, experienced by 38 participants, boosted IgG levels and neutralization above those induced by vaccination alone. Nevertheless, BA.1-specific neutralization remained significantly lower than wild-type, with BA.5-specific neutralization lower still. Higher Omicron BA.1-specific neutralization 1 month after third dose was an independent correlate of lower SARS-CoV-2 infection risk. Results underscore the immune benefits of the third COVID-19 mRNA vaccine dose in adults of all ages and identify vaccine-induced Omicron-specific neutralization as a correlate of protective immunity. Systemic antibody responses and functions however, particularly Omicron-specific neutralization, decline rapidly in COVID-19-naive individuals, particularly in older adults, supporting the need for additional booster doses.
Sections du résumé
Background
UNASSIGNED
Longer-term immune response data after 3 doses of coronavirus disease 2019 (COVID-19) mRNA vaccine remain limited, particularly among older adults and after Omicron breakthrough infection.
Methods
UNASSIGNED
We quantified wild-type- and Omicron-specific serum immunoglobulin (Ig)G levels, angiotensin-converting enzyme 2 displacement activities, and live virus neutralization up to 6 months after third dose in 116 adults aged 24-98 years who remained COVID-19 naive or experienced their first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during this time.
Results
UNASSIGNED
Among the 78 participants who remained COVID-19 naive throughout follow up, wild-type- and Omicron-BA.1-specific IgG concentrations were comparable between younger and older adults, although BA.1-specific responses were consistently significantly lower than wild-type-specific responses in both groups. Wild-type- and BA.1-specific IgG concentrations declined at similar rates in COVID-19-naive younger and older adults, with median half-lives ranging from 69 to 78 days. Antiviral antibody functions declined substantially over time in COVID-19-naive individuals, particularly in older adults: by 6 months, BA.1-specific neutralization was undetectable in 96% of older adults, versus 56% of younger adults. Severe acute respiratory syndrome coronavirus 2 infection, experienced by 38 participants, boosted IgG levels and neutralization above those induced by vaccination alone. Nevertheless, BA.1-specific neutralization remained significantly lower than wild-type, with BA.5-specific neutralization lower still. Higher Omicron BA.1-specific neutralization 1 month after third dose was an independent correlate of lower SARS-CoV-2 infection risk.
Conclusions
UNASSIGNED
Results underscore the immune benefits of the third COVID-19 mRNA vaccine dose in adults of all ages and identify vaccine-induced Omicron-specific neutralization as a correlate of protective immunity. Systemic antibody responses and functions however, particularly Omicron-specific neutralization, decline rapidly in COVID-19-naive individuals, particularly in older adults, supporting the need for additional booster doses.
Identifiants
pubmed: 36910697
doi: 10.1093/ofid/ofad073
pii: ofad073
pmc: PMC10003738
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofad073Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. The authors have no conflicts of interest to declare.
Références
J Infect Dis. 2022 Sep 21;226(6):983-994
pubmed: 35543278
Cell. 2022 Jul 7;185(14):2422-2433.e13
pubmed: 35772405
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
JAMA. 2021 Dec 7;326(21):2203-2204
pubmed: 34739043
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
EBioMedicine. 2022 Oct;84:104270
pubmed: 36130476
N Engl J Med. 2022 May 19;386(20):1910-1921
pubmed: 35320659
Cell Host Microbe. 2022 Sep 14;30(9):1231-1241.e6
pubmed: 35921836
Nat Commun. 2022 Aug 10;13(1):4686
pubmed: 35948557
Nat Microbiol. 2023 Jan;8(1):55-63
pubmed: 36593297
PLoS Med. 2022 Sep 1;19(9):e1003992
pubmed: 36048766
Vaccine. 2021 Nov 26;39(48):6984-6989
pubmed: 34763949
Sci Immunol. 2022 Feb 18;7(68):eabn8014
pubmed: 35076258
J Infect Dis. 2022 Apr 1;225(7):1129-1140
pubmed: 34888688
Lancet. 2021 Dec 4;398(10316):2093-2100
pubmed: 34756184
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Med (N Y). 2022 Dec 9;3(12):827-837.e3
pubmed: 36198311
Sci Immunol. 2022 Dec 23;7(78):eabp8328
pubmed: 35549298
Nature. 2022 Aug;608(7923):593-602
pubmed: 35714668
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Sci Transl Med. 2022 May 18;14(645):eabm2311
pubmed: 35348368
Emerg Microbes Infect. 2021 Dec;10(1):1495-1498
pubmed: 34232116
Nat Med. 2022 Sep;28(9):1785-1790
pubmed: 35760080
Science. 2022 Feb 18;375(6582):760-764
pubmed: 35050643
CMAJ. 2022 Dec 5;194(47):E1599-E1609
pubmed: 36507788
N Engl J Med. 2022 May 12;386(19):1804-1816
pubmed: 35263534
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Am J Pathol. 2022 Apr;192(4):642-652
pubmed: 35123975
Nature. 2022 Aug;608(7923):603-608
pubmed: 35790190
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
Nat Commun. 2022 Aug 1;13(1):4466
pubmed: 35915081
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281